Yes there is benefit to BENEFIT

American Journal of Transplantation

Volumn 11, Issue 3, 2011, Pages 634-

  Vincenti, Flavio ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BELATACEPT; CYCLOSPORIN A;

CHRONIC ALLOIMMUNE REJECTION; GLOMERULUS FILTRATION RATE; GRAFT REJECTION; GRAFT SURVIVAL; IMMUNOSUPPRESSIVE TREATMENT; LETTER; PRIORITY JOURNAL;

EID: 79951991726     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/j.1600-6143.2010.03412.x     Document Type: Letter

References (7)

1. Midtvedt K, Holdaas H. Belatacept. BENEFIT to the kidney? Am J Transplant 2010.
2. Vincenti F, Larsen C, Durrbach A et al., on behalf of the belatacept study group. Costimulation blockade with belatacept in renal transplantation. N Engl J Med 2005;353: 770-781. (Pubitemid 41215486)
3. Vincenti F, Charpentier B, Vaenterghem Y et al. A phase III study of belatacept-based immunosuppression regimens versus cyclosporine in renal transplant recipients (BENEFIT study). Am J Transplant 2010; 10: 535-546.
4. Durrbach A, Pestana JM, Pearson T et al. A phase III study of belatacept versus cyclosporine in kidney transplants from extended criteria donors (BENEFIT-EXT study). Am J Transplant 2010; 10: 547-557.
5. Ekberg H, Tedesco-Silva H, Demirbas A et al., for the ELITE-Symphony Study. Reduced exposure to calcineurin inhibitors in renal transplantation. New Engl J Med 2007; 357: 2562-2576.
6. Gaston RS, Cecka JM, Kasiske BL et al. Evidence for antibody-mediated injury as a major determinant of late kidney allograft failure. Transplantation 2010; 90: 68-74.
7. Vincenti F, Blancho G, Durrbach A et al. Five-year results of a phase II study with belatacept in renal transplantation. J Am Soc Nephrol 2010; 21: 1587-1596.